Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Raphael Borie
The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis
Abstract Pleuroparenchymal fibroelastosis (PPFE) is a progressive interstitial lung disease (ILD) with defining histology of intra-alveolar fibrosis with septal elastosis (AFE), suggesting unique cellular disease processes. Here, we present a binational single-nucleus RNA sequencing atlas of PPFE, based on explanted lungs from 40 patients.
Telomere length, common variants, and rare variants in IPF: a trio of key risk determinants
Get full text access Log in, subscribe or purchase for full access. References 1. Papiris, SA ∙ Kannengiesser, C ∙ Borie, R ∙ et al. Genetics in idiopathic pulmonary fibrosis: a clinical perspective Diagnostics. 2022; 12, 2928 2. Borie, R ∙ Kannengiesser, C ∙ Antoniou, K ∙ et al. European Respiratory Society statement on familial pulmonary fibrosis Eur Respir J. 2023; 61, 2201383 3. Ng, N ∙ Molina-Molina, M ∙ Adegunsoye, A ∙ et al.
The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis
Abstract Background: Pleuroparenchymal fibroelastosis (PPFE) is a progressive interstitial lung disease with higher prevalence in females, histologically characterized by intra-alveolar fibrosis with septal elastosis (AFE). Effective treatments are lacking, highlighting the need to dissect its pathogenesis at single-cell resolution.
Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial
Acknowledgements We gratefully acknowledge the patients for their participation in this trial. This study was supported by a grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique, 2015).
Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): one-year follow up results of a randomized controlled trial
Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: A. Versi has nothing to disclose.
European Respiratory Society guidelines for the Diagnosis and Management of Pulmonary Alveolar Proteinosis
Footnotes This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article. Conflict of Interest: A. Versi has nothing to disclose.
Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort
DLP and SJ are joint senior authors. DLP and SJ contributed equally. Correction notice This article has been corrected since it was published Online First. Figure 1 has been corrected. Contributors AM fulfilled the role of guarantor. DLP did the analysis. AM, DLP, PT and SJ cowrote the original draft.
Infections in autoimmune pulmonary alveolar proteinosis: a large retrospective cohort
DLP and SJ are joint senior authors. DLP and SJ contributed equally. Contributors AM fulfilled the role of guarantor. DLP did the analysis. AM, DLP, PT and SJ cowrote the original draft. AM, RB, LW-S, YU, EG, GP, MR-G, JT, EBergot, JC, SM-A, ABergeron, EBlanchard, BB, PB, ABourdin, PRB, SH, CHM, SQ, HN, CC, BC, YG, DM, CM, PT, VC, DLP and SJ contributed substantially to the investigation and data collection, as well to reviewing and editing the manuscript.
Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial
European Respiratory Journal 61: 2202071; DOI: 10.1183/13993003.02071-2022 Abstract Background Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy.
Impact of corticosteroids use on midterm sequelae in survivors of COVID‐19 admitted to hospital: A prospective cohort study
RESEARCH ARTICLE Jade Ghosn and Lila Bouadma contributed equally as last authors. Membership of the French COVID cohort study group and the French COVID cohort investigators group is provided in the Supporting Information. Abstract An understanding of the midterm sequelae in COVID-19 and their association with corticosteroids use are needed.
European Respiratory Society statement on familial pulmonary fibrosis
Introduction Genetic predisposition to pulmonary fibrosis is suggested by a 10-fold increase in disease prevalence in families of patients with a diagnosis of idiopathic pulmonary fibrosis (IPF) [1–3]. Initial studies of familial clustering of interstitial lung disease (ILD) led to the discovery of mutations in genes implicated in telomere homeostasis (telomere-related genes (TRGs)) and surfactant homeostasis (surfactant-related genes (SRGs)) (table 1 and ) [3, 4].
European Respiratory Society Statement on Familial Pulmonary Fibrosis
Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
COVID-19 in patients with Pulmonary Alveolar Proteinosis A European multicenter study
Thank you for your interest in spreading the word on European Respiratory Society . NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Targeted therapy for pulmonary alveolar proteinosis: the time is now
Francesco Bonella, Raphael Borie European Respiratory Journal 2022 59: 2102971; DOI: 10.1183/13993003.02971-2021 Abstract Gene therapy and impaired pathway correction are promising treatments for selected patients with pulmonary alveolar proteinosis syndrome https://bit.ly/3d9hjdS Footnotes Conflict of interest: F. Bonella reports personal fees and non-financial support from Boehringer Ingelheim, Roche, BMS, Galapagos, Sanofi, Fujirebio and Savara, outside the submitted work.
Systemic sclerosis‐associated interstitial lung disease treated with tocilizumab
Letter to the Editor Vincent Dauny, Service de Rhumatologie, Hôpital Bichat, Paris, France Search for more papers by this author Raphael Borie, Service de Rhumatologie, Hôpital Bichat, Paris, France Search for more papers by this author Marine Forien, Service de Rhumatologie, Hôpital Bichat, Paris, France Search for more papers by this author Mada Ghanem, Service de Rhumatologie, Hôpital Bichat, Paris, France Search for more papers by this author Elisabeth Palazzo, Service de Rhumatologie,...
Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort
Raphael Lhote, Isabella Annesi-Maesano, Hilario Nunes, David Launay, Raphael Borie, Karim Sacré, Nicolas Schleinitz, Mohamed Hamidou, Matthieu Mahevas, Hervé Devilliers, Philippe Bonniaud, François Lhote, Julien Haroche, Pierre Rufat, Zahir Amoura, Dominique Valeyre, Fleur Cohen Aubart European Respiratory Journal 2021 57: 2001160; DOI: 10.1183/13993003.01160-2020 Abstract Sarcoidosis is a rare disease of unknown cause with wide heterogeneity in clinical features and outcomes.
Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study
Loading metrics Open Access Peer-reviewed Research Article Raphael Borie, Laurent Savale, Antoine Dossier, Jade Ghosn, Camille Taillé, Benoit Visseaux, Kamel Jebreen, Abourahmane Diallo, Chloe Tesmoingt, Lise Morer, Tiphaine Goletto, Nathalie Faucher, Linda Hajouji, Catherine Neukirch, Mathilde Phillips, Sandrine Stelianides, Lila Bouadma, Solenn Brosseau, Sébastien Ottaviani, Johan Pluvy, Diane Le Pluart, Marie-Pierre Debray, Agathe Raynaud-Simon, Diane Descamps, Antoine Khalil, Jean...
Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multiethnic, multicenter cohort
Raphael Lhote, Isabella Annesi-Maesano, Hilario Nunes, David Launay, Raphael Borie, Karim Sacré, Nicolas Schleinitz, Mohamed Hamidou, Matthieu Mahevas, Hervé Devilliers, Philippe Bonniaud, François Lhote, Julien Haroche, Pierre Rufat, Zahir Amoura, Dominique Valeyre, Fleur Cohen Aubart European Respiratory Journal 2020; DOI: 10.1183/13993003.01160-2020 Abstract Background Sarcoidosis is a rare disease of unknown cause with wide heterogeneity in clinical features and outcomes.
Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study
Highlights • Response to corticosteroids in chronic hypersensitivity pneumonia is inconstant. • Rituximab could be considered as a therapeutic alternative. • Rituximab could stabilize or even improve lung function. Abstract Background There are chronic forms of hypersensitivity pneumonitis (cHP) that can progress to pulmonary fibrosis. There is no recommended treatment for patients whose respiratory condition continues to deteriorate in spite of antigen avoidance.
Functional assessment and phenotypic heterogeneity of SFTPA1 and SFTPA2 mutations in interstitial lung diseases and lung cancer
Marie Legendre, Afifaa Butt, Raphaël Borie, Marie-Pierre Debray, Diane Bouvry, Emilie Filhol-Blin, Tifenn Desroziers, Valérie Nau, Bruno Copin, Florence Dastot-Le Moal, Mélanie Héry, Philippe Duquesnoy, Nathalie Allou, Anne Bergeron, Julien Bermudez, Aurélie Cazes, Anne-Laure Chene, Vincent Cottin, Bruno Crestani, Jean-Charles Dalphin, Christine Dombret, Bérénice Doray, Clairelyne Dupin, Violaine Giraud, Anne Gondouin, Laurent Gouya, Dominique Israël-Biet, Caroline Kannengiesser, Aurélie Le...
The genetics of interstitial lung diseases
Raphael Borie, Pierre Le Guen, Mada Ghanem, Camille Taillé, Clairelyne Dupin, Philippe Dieudé, Caroline Kannengiesser, Bruno Crestani European Respiratory Review 2019 28: 190053; DOI: 10.1183/16000617.0053-2019 Abstract Interstitial lung diseases (ILDs) are a set of heterogeneous lung diseases characterised by inflammation and, in some cases, fibrosis.
Regulator of telomere length 1 (RTEL1) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes
Raphael Borie, Diane Bouvry, Vincent Cottin, Clement Gauvain, Aurélie Cazes, Marie-Pierre Debray, Jacques Cadranel, Philippe Dieude, Tristan Degot, Stephane Dominique, Anne Sophie Gamez, Madeleine Jaillet, Pierre-Antoine Juge, Arturo Londono-Vallejo, Arnaud Mailleux, Hervé Mal, Catherine Boileau, Christelle Menard, Hilario Nunes, Gregoire Prevot, Sebastien Quetant, Patrick Revy, Julie Traclet, Lidwine Wemeau-Stervinou, Marie Wislez, Caroline Kannengiesser, Bruno Crestani European Respiratory...
Regulator of telomere length 1 (RTEL1) mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes
Abstract RTEL1 mutations have been evidenced in 5–9% of familial pulmonary fibrosis, but the phenotype of patients with interstitial lung disease (ILD) and RTEL1 mutations is poorly known. Whole exome sequencing was performed in 252 probands with ILD and we included all patients with ILD and RTEL1 mutation. RTEL1 expression was evaluated by immunochemistry in the lung of controls, RTEL1 and TERT mutation carriers. We identified 35 subjects, from 17 families.
Treatment of cardiac sarcoidosis: A comparative study of steroids and steroids plus immunosuppressive drugs
Publication History Published online: November 30, 2018Accepted: November 28, 2018; Received in revised form: November 6, 2018; Received: October 2, 2018;
Pneumocystosis revealing immunodeficiency secondary to TERC mutation
Pneumocystosis revealing immunodeficiency secondary to TERC mutation Raphael Borie, Caroline Kannengiesser, Flore Sicre de Fontbrune, David Boutboul, Laure Tabeze, Florence Brunet, Elodie Lainey, Marie Pierre Debray, Aurélie Cazes, Bruno Crestani European Respiratory Journal Nov 2017, 50 (5) 1701443; DOI: 10.1183/13993003.01443-2017
Heterogeneity of lung disease associated with NK2 homeobox 1 mutations
Publication HistoryPublished online: May 26, 2017Accepted: May 25, 2017; Received in revised form: April 13, 2017; Received: October 23, 2016;
Management of suspected monogenic lung fibrosis in a specialised centre
Telomerase complex mutationsGenetic mutations and complex inheritanceThe telomerase complex catalyses the addition of repeated DNA sequences in the telomere region, thereby protecting chromosomes against loss of material during mitoses [26].
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis Raphael Borie, Laure Tabèze, Gabriel Thabut, Hilario Nunes, Vincent Cottin, Sylvain Marchand-Adam, Grégoire Prevot, Abdellatif Tazi, Jacques Cadranel, Herve Mal, Lidwine Wemeau-Stervinou, Anne Bergeron Lafaurie, Dominique Israel-Biet, Clement Picard, Martine Reynaud Gaubert, Stephane Jouneau, Jean-Marc Naccache, Julie Mankikian, Christelle Ménard, Jean-François Cordier, Dominique Valeyre, Marion...
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis
Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis Raphael Borie, Laure Tabèze, Gabriel Thabut, Hilario Nunes, Vincent Cottin, Sylvain Marchand-Adam, Grégoire Prevot, Abdellatif Tazi, Jacques Cadranel, Herve Mal, Lidwine Wemeau-Stervinou, Anne Bergeron Lafaurie, Dominique Israel-Biet, Clement Picard, Martine Reynaud Gaubert, Stephane Jouneau, Jean-Marc Naccache, Julie Mankikian, Christelle Ménard, Jean-François Cordier, Dominique Valeyre, Marion...
Pulmonary mucosa-associated lymphoid tissue lymphoma revisited
Pulmonary mucosa-associated lymphoid tissue lymphoma revisited Raphael Borie, Marie Wislez, Martine Antoine, Christiane Copie-Bergman, Catherine Thieblemont, Jacques Cadranel European Respiratory Journal Oct 2016, 48 (4) 1252; DOI: 10.1183/13993003.01143-2016
Phenotype heterogeneity in a familial “brain lung thyroid syndrome” related to a novel NKX-2.1 mutation
Phenotype heterogeneity in a familial “brain lung thyroid syndrome” related to a novel NKX-2.1 mutation Nadia Nathan, Raphaël Borie, Sophie Jovien, Diane Doummar, Malek Louha, Julie Beucher, Mélanie Henriat, Estelle Breton, Annick Clement European Respiratory Journal Sep 2016, 48 (suppl 60) PA3889; DOI: 10.1183/13993003.congress-2016.PA3889
Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation
Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation Aurélien Justet, Raphael Borie, Hilario Nunes, Vincent Cottin, Sylvain Marchand Adam, Jacques Cadranel, Emmanuel Bergot, Lidwine Wemeau-Stervineau, Jean Marc Naccache, Eline Magois, Irene Frachon, Anne Gondouin, Anas Medhaoui, Jean Francois Cordier, Dominique Valeyre, Bernard Grandchamp, Caroline Kanengiesser, Bruno Crestani European Respiratory Journal Sep 2016, 48 (suppl 60) OA484; DOI:...
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Raphael
Contact Raphael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack